Legal status · United Kingdom
Is Idebenone legal in the United Kingdom?
Written by Aaron CuhaReviewed Sep 2026
Direct answer
No. Idebenone is not an approved medicine in the United Kingdom; its classification is "Prescription medicine in the European Union (Raxone)". Nothing containing it is authorized for any use in people. Vials labeled "for research use only" are not exempt: that label does not make human use lawful. On the evidence, 5 human studies are cited on its profile.
Idebenone in the United Kingdom at a glance
| Classification | Prescription medicine in the European Union (Raxone) |
|---|---|
| Note | Raxone holds an EU marketing authorisation granted in September 2015, under exceptional circumstances, for Leber hereditary optic neuropathy. Current Great Britain licensing status was not verified for this entry. |
| MHRA approval status | Not approved by MHRA |
| Human studies cited | 5 of 6 citations on the profile |
| Reviewed | Sep 2026 |
Classification and note come from the Idebenone profile, checked against Medicines and Healthcare products Regulatory Agency (MHRA) listings at the reviewed date.
What this means
- 01
No product containing Idebenone is approved by MHRA for any use in the United Kingdom, so nothing on the market is authorized for people.
- 02
"Research use only" is a vendor label, not a legal category that permits human use. It does not exempt a product from medicines law.
- 03
Importing, supplying or promoting it for human use can fall under medicines legislation in the United Kingdom. This page is general information, not legal advice.
What Idebenone is
Authorised in the European Union for one rare mitochondrial optic neuropathy, granted under exceptional circumstances because the normal evidence standard was not met. The randomised trial that supported it missed its primary endpoint, and the trials in Alzheimer's disease and Friedreich ataxia were negative.
Idebenone is three separate products wearing one name, and they should not be read as supporting each other. The medicine.
Mechanism: A short-chain benzoquinone that can accept electrons from cytosolic NAD(P)H quinone dehydrogenase 1 and deliver them to complex III, bypassing a defective complex I. That is a coherent rationale for a disease caused by complex I mutations, which is what Leber hereditary optic neuropathy is, and it is why the drug found its indication there rather than in general antioxidant use.
Regulatory history: Not FDA approved for any indication. Authorised in the European Union as Raxone for Leber hereditary optic neuropathy since September 2015, under exceptional circumstances. Separately sold in topical skincare and in oral nootropic supplements, neither of which is an approved use.
How MHRA treats this kind of product
Licenses medicines for the UK market. A compound without a marketing authorisation is an unlicensed medicine, which can only lawfully be supplied for human use through a prescriber under the specials scheme, not sold as a research product.
The classification above is the The Longevity Archive reading of Medicines and Healthcare products Regulatory Agency listings for Idebenone at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.
Idebenone in other countries
Frequently asked questions
Is Idebenone legal in the United Kingdom?
No. Idebenone is not an approved medicine in the United Kingdom; its classification is "Prescription medicine in the European Union (Raxone)". Nothing containing it is authorized for any use in people. Vials labeled "for research use only" are not exempt: that label does not make human use lawful. On the evidence, 5 human studies are cited on its profile. Note: Raxone holds an EU marketing authorisation granted in September 2015, under exceptional circumstances, for Leber hereditary optic neuropathy. Current Great Britain licensing status was not verified for this entry.
Can I buy Idebenone in the United Kingdom?
No approved product exists to buy. In the United Kingdom Idebenone is classified as "Prescription medicine in the European Union (Raxone)", so there is no licensed pharmacy product. Vendors selling it "for research use only" are not selling it for human use, and that label does not change its legal status. This site does not list or recommend vendors. Note: Raxone holds an EU marketing authorisation granted in September 2015, under exceptional circumstances, for Leber hereditary optic neuropathy. Current Great Britain licensing status was not verified for this entry.
Is Idebenone MHRA approved?
No. In the United Kingdom Idebenone is classified as "Prescription medicine in the European Union (Raxone)", which is not a MHRA marketing approval. For comparison, the US FDA status is: Not FDA approved for any indication. Authorised in the European Union as Raxone for Leber hereditary optic neuropathy since September 2015, under exceptional circumstances. Separately sold in topical skincare and in oral nootropic supplements, neither of which is an approved use.. On the evidence, 5 human studies are cited on its profile.
Related compounds in the United Kingdom
Full research profile
Mechanism, cited studies, FDA status and the full legal summary for Idebenone live on its compound profile.
Idebenone profileThis page is general information about the regulatory status of Idebenone in the United Kingdom, current as of Sep 2026. It is not legal advice, and classifications change; check Medicines and Healthcare products Regulatory Agency directly or consult a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships and does not recommend where to buy anything.